Free Trial

Soleno Therapeutics (SLNO) Stock Price, News & Analysis

Soleno Therapeutics logo
$59.21 +1.23 (+2.12%)
Closing price 10/3/2025 04:00 PM Eastern
Extended Trading
$58.52 -0.69 (-1.16%)
As of 10/3/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Soleno Therapeutics Stock (NASDAQ:SLNO)

Advanced

Key Stats

Today's Range
$56.50
$60.29
50-Day Range
$49.71
$86.47
52-Week Range
$41.50
$90.32
Volume
1.62 million shs
Average Volume
2.69 million shs
Market Capitalization
$3.15 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$115.09
Consensus Rating
Moderate Buy

Company Overview

Soleno Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
84th Percentile Overall Score

SLNO MarketRank™: 

Soleno Therapeutics scored higher than 84% of companies evaluated by MarketBeat, and ranked 168th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Soleno Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 11 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    Soleno Therapeutics has a consensus price target of $115.09, representing about 94.4% upside from its current price of $59.21.

  • Amount of Analyst Coverage

    Soleno Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Soleno Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Soleno Therapeutics are expected to grow in the coming year, from ($3.72) to ($2.60) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Soleno Therapeutics is -14.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Soleno Therapeutics is -14.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Soleno Therapeutics has a P/B Ratio of 10.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Soleno Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    15.75% of the float of Soleno Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Soleno Therapeutics has a short interest ratio ("days to cover") of 4.
  • Change versus previous month

    Short interest in Soleno Therapeutics has recently decreased by 4.35%, indicating that investor sentiment is improving.
  • Dividend Yield

    Soleno Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Soleno Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    15.75% of the float of Soleno Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Soleno Therapeutics has a short interest ratio ("days to cover") of 4.
  • Change versus previous month

    Short interest in Soleno Therapeutics has recently decreased by 4.35%, indicating that investor sentiment is improving.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for Soleno Therapeutics this week, compared to 8 articles on an average week.
  • Search Interest

    32 people have searched for SLNO on MarketBeat in the last 30 days. This is an increase of 433% compared to the previous 30 days.
  • MarketBeat Follows

    5 people have added Soleno Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Soleno Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 6.40% of the stock of Soleno Therapeutics is held by insiders.

  • Percentage Held by Institutions

    97.42% of the stock of Soleno Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Soleno Therapeutics' insider trading history.
Receive SLNO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Soleno Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

SLNO Stock News Headlines

This soon could be the most precious company in America
Currently, a brand-new, all-American factory outside San Antonio is becoming the most significant site in the tech world… It’s the only U.S. plant capable of mass-producing a new material… one that every tech giant desperately needs.tc pixel
See More Headlines

SLNO Stock Analysis - Frequently Asked Questions

Soleno Therapeutics' stock was trading at $44.95 at the beginning of the year. Since then, SLNO shares have increased by 31.7% and is now trading at $59.21.

Soleno Therapeutics, Inc. (NASDAQ:SLNO) released its quarterly earnings data on Wednesday, August, 6th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.53) by $0.44. The business had revenue of $32.66 million for the quarter, compared to the consensus estimate of $3.91 million.
Read the conference call transcript
.

Shares of Soleno Therapeutics reverse split on Friday, August 26th 2022.The 1-15 reverse split was announced on Friday, August 26th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Shares of SLNO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Soleno Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), e.l.f. Beauty (ELF), Disc Medicine (IRON), Arista Networks (ANET) and Adobe (ADBE).

Company Calendar

Last Earnings
8/06/2025
Today
10/05/2025
Next Earnings (Estimated)
11/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:SLNO
CIK
1484565
Employees
30
Year Founded
1999

Price Target and Rating

High Price Target
$145.00
Low Price Target
$105.00
Potential Upside/Downside
+94.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.92
Research Coverage
13 Analysts

Profitability

EPS (Trailing Twelve Months)
($4.14)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$175.85 million
Net Margins
N/A
Pretax Margin
-554.49%
Return on Equity
-73.74%
Return on Assets
-56.67%

Debt

Debt-to-Equity Ratio
0.21
Current Ratio
15.13
Quick Ratio
15.01

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$5.68 per share
Price / Book
10.42

Miscellaneous

Outstanding Shares
53,150,000
Free Float
49,744,000
Market Cap
$3.15 billion
Optionable
Optionable
Beta
-2.75

Social Links

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:SLNO) was last updated on 10/6/2025 by MarketBeat.com Staff
From Our Partners